CBP seized over 5,000 peptide shipments in a recent enforcement action involving misdeclared, consolidated imports. The case underscores how documentation and labeling issues can trigger seizures for regulated goods overseen by the U.S. Customs and Border Protection and the U.S. Food and Drug Administration. Importers remain responsible for compliance, but we help evaluate seizures, respond to CBP, and develop strategies to resolve issues and reduce future risk.
